2018, Number 4
<< Back Next >>
Med Int Mex 2018; 34 (4)
Effect of the administration of vitamin K on the complications associated with end stage liver disease
Álvarez-Saucedo R, Santoyo-Sánchez A, Galván-Flores F, Álvarez-Espinoza MÁ, Durán-Guzmán R, Salcedo-Roldán M, Ramos-Peñafiel C
Language: Spanish
References: 34
Page: 551-556
PDF size: 254.83 Kb.
ABSTRACT
Background: The administration of vitamin K are restricted to situations such as
an antidote for vitamin K antagonists and hemorrhagic disease of the newborn, but due
to its role in hemostasis, its use has been extended to other diseases, such as terminal
chronic liver disease.
Objective: To identify the efficacy of adding vitamin K to the management of patients
with terminal hepatic insufficiency with some state of decompensation.
Material and Method: A retrospective case-control study was done between
2016-2017 in patients with Child-Pugh C chronic liver disease during an episode of
decompensation. Vitamin K (menadione sodium bisulfite) was administered at a dose
of 10 mg intramuscular every 12 h for three days.
Results: A total of 60 patients were studied, 30 received vitamin K, in the case of
a hemorrhagic event, replacement therapy with fresh frozen plasma and cryoprecipitates
were administered together. The mean age was 60 (25-86) years; all were male.
Hemorrhage (85%) was the main cause of complication. Five cases (8.3%) died due
to reactivation of the hemorrhage. The administration of vitamin K did not shorten the
coagulation tests (TP, aPTT, INR) nor showed a mortality benefit. Only thrombosis such
as encephalopathy showed an association on mortality.
Conclusion: The addition of vitamin K does not influence the complications in
patients with terminal liver disease.
REFERENCES
Ertel AE, Chang AL, Kim Y, Shah SA. Management of gastrointestinal bleeding in patients with cirrhosis. Curr Prob Surg 2016;53(8):366-395.
Lisman T, Stravitz RT. Rebalanced hemostasis in patients with acute liver failure. Semin Thromb Hemost 2015;41(5):468-473.
Lisman T, Leebeek FW. Hemostastic alteration in liver disease: a review on pathophysiology, clinical consequences and treatment. Dig Surg 2007;24(4):250-258.
Weeder PD, Porte RJ Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transf Med Rev 2014;28(3):107-113.
Reddy SS, Civan JM. From Child- Pugh to model for endstage liver disease: deciding who needs a liver transplant. Med Clin North Am 2016;100(3):449-464.
Dogan S, Gurakar A. Liver transplantation update: 2014. Euroasian J Hepatogastroenterol 2015;5(2):98-106.
Kaira A, Weed JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more. Curr Opin Organ Transplant 2016;21(2):120-126.
Machicao VI. Model for end -stage liver disease-sodium score: the evolution in the prioritization of liver transplantation. Clin Liver Dis 2017;21(2):275-287.
El Serafy MA, Kassem AM, Omar H, Mahfouz MS, El Said El Raziky M. APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV post liver fibrosis: Systematic review and meta-analysis. Arab J Gastroenterol 2017;18(2):51 -57.
Khan DA, Fatima-Tuz-Zuhra, Khan FA, Mubarak A. Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients. J Ayub Med Coll Abbottabad 2008;20(4):122-126.
García-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascitis and spontaneous bacterial peritonitis. Dig Dis 2016;34(4):382-386.
Poordad FF. Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin 2015;31(5):925-937.
Hartmann M, Szalai C, Saner FH. Hemostasis in liver transplantation: Pathophysiology, monitoring and treatment. World J Gastroenterol 2016;22(4):1541-1550.
Forkin KT, Colquhoun DA, Nemerqut ECM Huffmyer JL. The coagulation profile of end-stage liver disease and considerations for intraoperative management. Anesth Analg 2018;126(1):46-61.
Fahrendorff M, Oliveri RS, Johansson P. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products - A systematic review and metaanalysis. Scand J Trauma Resusc Emerg Med 2017;25(1):39.
Shah NL, Intagliata NM, Northup PG, Argo CK, Caldwell SH. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol 2014;11(11):675-682.
Martí-Carbajal AJ, Cortés-Jofre M, Martí-Peña AJ. Vitamin K for upper gastrointestinal bleeding in patients with liver diseases. Cochrane Database Syst Rev 2008;16(3):CDD004792.
Martí-Carvajal AJ, Solà I. Vitamin K for upper gastrointestinal bleeding in patients with acute or chronic liver diseases. Cochrane Database Syst Rev 2012 12;(9):CD004792.
Martí-Carvajal AJ, Solà I. Vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseases. Cochrane Database Syst Rev 2015;(6):CD004792.
Garbuzenko DV. Current approaches to the management of patients with liver cirrhosis who have acute esophageal variceal bleeding. Curr Med Res Opin 2016;32(3):467-475.
Biecker E. Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol 2013;19(31):5035- 5050.
Brunner F, Berziqotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017; Liver Int 2017;37(S1):104-115.
Kravetz D. Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations. J Clin Gastroenterol 2007;41(S3):S318-S322.
Salim A, Malik K, Farooq MO, Butt U, Butt AK, Alam A. Early initiation of beta blockers following primary endoscopic therapy for bleeding of esophageal varices in cirrhotics. J Ayub Med Coll Abbottabad 2017;29(2):186-189.
Burza MA, Marschall HU, Napoleone L, Molinaro A. The 35 -years odyssey of betablockers in cirrhosis: any gender difference in sight? Pharmacol Res 2017;119:20-26.
Aggarwal A, Puri K, Lianqpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review. World J Gastroenterol 2014;20(19):5737-5745.
Ha NB, Regal RE. Anticoagulation in patients with cirrhosis: caught between a rock-liver and a hard place. Ann Pharmacother 2016;50(5):402-409.
Violi F, Corazza GR, Caldwell SH, Perticone F, Gatta A, Angelico M, et al. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Intern Emerg Med 2016;11(8):1059-1066.
Gîrleanu I, Trifan A, Cojocariu C, Sîngeap AM, et al. The risk of thrombotic events in patients with liver cirrhosis. Rev Med Chir Soc Med Nat Iasi 2012;116(4):991-996.
Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 1995;22(3):876-82.
Carr BI, Wang Z, Kar S. K vitamins, PTP antagonism, and cell growth arrest. J Cell Physiol 2002;193(3):263-274.
Toyoda H, Kumada T, Tada T, Yama T, et al. Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Sci 2017;108(12):2438-2444.
Meguro M, Mizuguchi T, Nishidate T, Okita K, et al. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015;21(16):4933-4945.
Li B, Li B, Guo T, Sun Z, Li X, Li X, et al. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget 2017;17;8(46):80521-80530.
Full text